197894-84-1

Usage

Uses

(+)-CI 1044, is an orally active PDE4 inhibitor.

Upstream product

• 59-67-6 nicotinic acid 
• 197895-08-2 (R)-3,9-diamino-1-phenyl-6,7-dihydro-3H-[1,4]diazepino[6,7,1-hi]indol-4-one 
• 126149-54-0 (RS)-3-amino-5-phenyl-3,4,6,7,-tetrahydropyrrolo<3,2,1-jk><1,4>benzodiazepin-4(3H)-one 
• 126252-50-4 (3R)-3-amino-5-phenyl-3,4,6,7-tetrahydropyrrolo<3,2,1-jk><1,4>benzodiazepin-4(3H)-one 
• 27158-79-8 1-phenyl-6,7-dihydro-3H-[1,4]diazepino[6,7,1-hi]indol-4-one 
• 197895-07-1 (R)-3-amino-9-nitro-1-phenyl-6,7-dihydro-3H-[1,4]diazepino[6,7,1-hi]indol-4-one 
• 126167-36-0 1-phenyl-6,7-dihydro[1,4]diazepino[6,7,1-hi]indole-3,4-dione 3-oxime 

Relevant academic research and scientific papers

Diazepinoindoles for the treatment of chronic obstructive pulmonary disease

The present invention relates to the use of diazepinoindoles of the formula (I): in which A is aryl or nitrogen-containing heteroaryl, and B is a hydroxyl or amino radical, for the treatment of chronic obstructive pulmonary disease.

Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indoles: Discovery of potent, selective phosphodiesterase type 4 inhibitors

The synthesis, structure-activity relationships, and biological properties of a novel series of potent and selective phosphodiesterase type 4 (PDE4) inhibitors are described. These new aminodiazepinoindoles displayed in vitro PDE4 activity with submicromo

Diazepinoindoles as phosphodiesterase 4 inhibitors

Diazepinoindoles of formula (I), STR1 wherein A is mono- to trisubstituted aryl or heteroaryl, and B is an --OR1 or --NR2 R3 group where R1, R2 and R3 are particularly hydrogen, and racemic